Heidi Anne Duerr, MPH

Curiosity, rapport, and understanding lived experience can strengthen schizophrenia care and treatment engagement, according to Tracy Hicks, DNP.

Tracy Hicks, DNP, FNP/PMHNP-BC, outlines how personalized, team-based care and shared decision-making can improve schizophrenia outcomes in real-world practice.

New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

The SPAN survey underscores gaps in schizophrenia care access as new treatments emerge, citing coverage and continuity challenges.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.

Along with a new name, the new edition aims to address concerns and critiques of past DSM editions.

Douglas Leffa, MD, PhD, shares highlights from a poster at the APSARD conference examining severity and age of diagnosis.

Therapeutic drug monitoring revolutionizes psychiatric care, enhancing treatment precision and patient outcomes through real-time data and personalized medicine strategies.

Gerald Maguire, MD, discusses the unmet needs of patients with comorbid ADHD and stuttering.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

From APSARD 2026, a patient journey demonstrates opportunities in psychiatric education on stuttering and emerging treatment approaches.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Explore the complex relationship between gender, sexual health, and mental health with insights from expert Eugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

Gerald A. Maguire, MD, explores the importance of understanding stuttering in psychiatry, emphasizing the need for research, collaborative care, and awareness.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

Half of patients with stuttering also experience anxiety, highlighting the psychiatrist’s role in care and support.

Because stuttering represents a spectrum disorder, a spectrum of treatments are needed.

Shelly Jo Kraft, MS, PhD, lays the foundation for a new approach that emphasizes the role of comorbidities in stuttering.

Shahriar SheikhBahaei, PhD, discusses how animal models may lead to better treatments.

Collaborating with speech pathologists and others improve care for patients who stutter.

Shahriar SheikhBahaei, PhD, shares insights into the neurobiology of stuttering at STARS conference.

Gerald A. Maguire, MD, details the unmet needs in stuttering at the inaugural conference.